Eton Pharmaceuticals Receives FDA Extension for NDA for ET-400On February 6, 2025, Eton Pharmaceuticals, Inc. announced through a press release that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) g

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Eton Pharmaceuticals’s 8K filing here. About Eton Pharmaceuticals (Get Free Report) Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers […]

Leave a Reply

Your email address will not be published.

Previous post Matinas Biopharma Appoints Evelyn D’An as Director and Audit Committee Chair
Next post Arrow Electronics (NYSE:ARW) Updates Q1 2025 Earnings Guidance